Krebs Income Before Tax vs Other Operating Expenses Analysis

KREBSBIO   104.14  8.79  7.78%   
Krebs Biochemicals financial indicator trend analysis is infinitely more than just investigating Krebs Biochemicals and recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Krebs Biochemicals and is a good investment. Please check the relationship between Krebs Biochemicals Income Before Tax and its Other Operating Expenses accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krebs Biochemicals and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Income Before Tax vs Other Operating Expenses

Income Before Tax vs Other Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Krebs Biochemicals and Income Before Tax account and Other Operating Expenses. At this time, the significance of the direction appears to have pay attention.
The correlation between Krebs Biochemicals' Income Before Tax and Other Operating Expenses is -0.79. Overlapping area represents the amount of variation of Income Before Tax that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of Krebs Biochemicals and, assuming nothing else is changed. The correlation between historical values of Krebs Biochemicals' Income Before Tax and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Before Tax of Krebs Biochemicals and are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Income Before Tax i.e., Krebs Biochemicals' Income Before Tax and Other Operating Expenses go up and down completely randomly.

Correlation Coefficient

-0.79
Relationship DirectionNegative 
Relationship StrengthWeak

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Krebs Biochemicals income statement and is an important metric when analyzing Krebs Biochemicals and profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Krebs Biochemicals and. It is also known as Krebs Biochemicals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Most indicators from Krebs Biochemicals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Krebs Biochemicals and current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krebs Biochemicals and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
The current Selling General Administrative is estimated to decrease to about 5.7 M. The current Issuance Of Capital Stock is estimated to decrease to about 61.2 M
 2021 2022 2023 2024 (projected)
Total Operating Expenses195.1M488.0M46.2M43.8M
Cost Of Revenue737M256.8M613.0M342.2M

Krebs Biochemicals fundamental ratios Correlations

0.090.610.590.17-0.850.850.490.30.00.49-0.64-0.1-0.510.88-0.340.30.320.88-0.540.97-0.260.2-0.890.670.82
0.090.270.120.010.160.390.170.2-0.130.840.46-0.250.740.460.310.330.330.440.70.220.02-0.31-0.18-0.19-0.08
0.610.270.870.07-0.780.540.950.23-0.190.65-0.05-0.43-0.030.78-0.10.110.670.76-0.110.69-0.260.09-0.870.310.54
0.590.120.870.0-0.740.520.880.05-0.210.5-0.14-0.4-0.140.69-0.180.160.40.66-0.240.69-0.310.01-0.790.530.66
0.170.010.070.0-0.310.14-0.040.55-0.07-0.05-0.290.14-0.230.070.68-0.04-0.110.30.170.070.790.11-0.13-0.23-0.17
-0.850.16-0.78-0.74-0.31-0.65-0.7-0.330.12-0.320.610.210.61-0.750.2-0.13-0.39-0.790.57-0.810.15-0.270.91-0.55-0.71
0.850.390.540.520.14-0.650.410.24-0.040.73-0.53-0.05-0.170.87-0.270.460.360.84-0.240.83-0.180.11-0.810.580.62
0.490.170.950.88-0.04-0.70.41-0.02-0.210.550.03-0.430.010.67-0.17-0.070.620.62-0.140.57-0.250.04-0.760.240.46
0.30.20.230.050.55-0.330.24-0.02-0.060.19-0.28-0.18-0.180.260.540.210.080.420.180.290.09-0.04-0.320.030.06
0.0-0.13-0.19-0.21-0.070.12-0.04-0.21-0.06-0.22-0.160.86-0.1-0.18-0.31-0.32-0.03-0.17-0.01-0.03-0.050.480.130.270.04
0.490.840.650.5-0.05-0.320.730.550.19-0.220.16-0.370.460.80.00.430.530.740.320.59-0.18-0.21-0.640.150.31
-0.640.46-0.05-0.14-0.290.61-0.530.03-0.28-0.160.16-0.310.81-0.30.32-0.130.12-0.340.71-0.480.05-0.340.42-0.62-0.5
-0.1-0.25-0.43-0.40.140.21-0.05-0.43-0.180.86-0.37-0.31-0.14-0.34-0.23-0.24-0.23-0.3-0.04-0.210.290.450.30.14-0.13
-0.510.74-0.03-0.14-0.230.61-0.170.01-0.18-0.10.460.81-0.14-0.130.270.110.23-0.190.87-0.370.1-0.330.31-0.48-0.47
0.880.460.780.690.07-0.750.870.670.26-0.180.8-0.3-0.34-0.13-0.210.350.510.97-0.220.93-0.30.04-0.90.480.7
-0.340.31-0.1-0.180.680.2-0.27-0.170.54-0.310.00.32-0.230.27-0.21-0.11-0.19-0.010.66-0.320.65-0.340.25-0.61-0.58
0.30.330.110.16-0.04-0.130.46-0.070.21-0.320.43-0.13-0.240.110.35-0.110.260.310.040.37-0.210.11-0.30.410.47
0.320.330.670.4-0.11-0.390.360.620.08-0.030.530.12-0.230.230.51-0.190.260.460.090.42-0.310.48-0.530.220.36
0.880.440.760.660.3-0.790.840.620.42-0.170.74-0.34-0.3-0.190.97-0.010.310.46-0.170.91-0.130.07-0.880.40.63
-0.540.7-0.11-0.240.170.57-0.24-0.140.18-0.010.320.71-0.040.87-0.220.660.040.09-0.17-0.430.38-0.310.36-0.57-0.61
0.970.220.690.690.07-0.810.830.570.29-0.030.59-0.48-0.21-0.370.93-0.320.370.420.91-0.43-0.360.16-0.90.690.87
-0.260.02-0.26-0.310.790.15-0.18-0.250.09-0.05-0.180.050.290.1-0.30.65-0.21-0.31-0.130.38-0.36-0.120.28-0.57-0.55
0.2-0.310.090.010.11-0.270.110.04-0.040.48-0.21-0.340.45-0.330.04-0.340.110.480.07-0.310.16-0.12-0.130.390.34
-0.89-0.18-0.87-0.79-0.130.91-0.81-0.76-0.320.13-0.640.420.30.31-0.90.25-0.3-0.53-0.880.36-0.90.28-0.13-0.58-0.75
0.67-0.190.310.53-0.23-0.550.580.240.030.270.15-0.620.14-0.480.48-0.610.410.220.4-0.570.69-0.570.39-0.580.87
0.82-0.080.540.66-0.17-0.710.620.460.060.040.31-0.5-0.13-0.470.7-0.580.470.360.63-0.610.87-0.550.34-0.750.87
Click cells to compare fundamentals

Krebs Biochemicals Account Relationship Matchups

Krebs Biochemicals fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding16.6M18.0M19.6M21.6M24.8M15.6M
Total Assets1.3B1.6B1.9B1.7B1.8B1.3B
Short Long Term Debt Total812.1M1.1B1.4B1.8B2.4B2.5B
Other Current Liab165.0M274.2M148.1M237.0M326.9M343.2M
Total Current Liabilities431.3M481.9M780.6M491.0M618.3M539.4M
Total Stockholder Equity(250.0M)(427.3M)(750.9M)(994.6M)(1.2B)(1.1B)
Property Plant And Equipment Net1.1B1.3B1.4B1.5B1.5B1.1B
Net Debt811.6M998.4M580.7M1.8B2.4B2.5B
Accounts Payable200.3M207.8M379.1M152.8M189.7M207.4M
Cash560K7.1M324K858K1.4M1.3M
Non Current Assets Total1.1B1.4B1.5B1.6B1.6B1.4B
Non Currrent Assets Other54.6M57.0M(1K)51.5M89.6M169.8M
Cash And Short Term Investments560K10.8M324K3.7M1.4M1.3M
Net Receivables2.8M3.0M19.5M6.5M47.3M66.4M
Liabilities And Stockholders Equity1.3B1.6B1.9B1.7B1.8B1.3B
Non Current Liabilities Total1.2B1.5B1.9B2.3B2.4B1.3B
Inventory150.0M166.0M255.6M119.5M102.4M145.7M
Other Current Assets34.1M34.4M79.5M29.7M23.3M32.0M
Other Stockholder Equity1.1B(623.5M)1.2B1.3B1.5B1.6B
Total Liab1.6B2.0B2.6B2.7B3.0B1.8B
Total Current Assets188.6M214.2M354.9M160.6M174.4M278.7M
Accumulated Other Comprehensive Income(1.3B)(1.4B)152.2M110.5M114.4M120.2M
Common Stock166.3M180.0M196.2M215.6M247.9M154.5M
Short Term Debt11.6M105.9M101.7M101.2M101.8M128.9M
Current Deferred Revenue110.5M(105.9M)151.8M115.4M132.7M121.4M
Retained Earnings(1.5B)(1.8B)(2.3B)(2.5B)(2.7B)(2.6B)
Intangible Assets37.7M35.1M28.7M26.9M25.0M27.7M
Other Liab515.7M501.6M532.1M539.0M619.9M439.3M
Net Tangible Assets(161.4M)(268.4M)(445.8M)(769.4M)(692.5M)(657.8M)
Other Assets73.8M96.0M82.5M27.1M24.4M23.2M
Long Term Debt655.1M1.0B1.3B1.7B1.8B1.9B
Deferred Long Term Liab21.8M19.2M16.6M10.2M9.2M8.8M
Short Long Term Debt7.1M105.9M99.9M99.9M99.3M113.0M
Property Plant Equipment1.1B1.3B1.4B1.5B1.7B1.1B
Long Term Debt Total655.1M1.0B1.3B1.7B2.0B2.1B
Cash And Equivalents4.2M147M0.0(1K)(900.0)(855.0)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Krebs Stock

Balance Sheet is a snapshot of the financial position of Krebs Biochemicals and at a specified time, usually calculated after every quarter, six months, or one year. Krebs Biochemicals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Krebs Biochemicals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Krebs currently owns. An asset can also be divided into two categories, current and non-current.